Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martín García-Sancho A, Provencio Pulla M, Trněný M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J. Zinzani PL, et al. Among authors: kingsley e. J Clin Oncol. 2023 Nov 20;41(33):5107-5117. doi: 10.1200/JCO.23.00775. Epub 2023 Jul 28. J Clin Oncol. 2023. PMID: 37506346 Clinical Trial.
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
Castillo JJ, Kingsley EC, Narang M, Yimer HA, Dasanu CA, Melear JM, Coleman M, Farber CM, Shulman J, Mantovani EH, Zhang X, Cohen A, Huang J. Castillo JJ, et al. Among authors: kingsley ec. EJHaem. 2023 Jan 11;4(1):301-304. doi: 10.1002/jha2.619. eCollection 2023 Feb. EJHaem. 2023. PMID: 36819162 Free PMC article. No abstract available.
Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
Xu L, Shadman M, Flinn IW, Levy MY, Porter R, Burke JM, Zafar SF, Cultrera JL, Misleh J, Kingsley EC, Yimer HA, Freeman B, Chaudhry A, Tumula PK, Gandhi MD, Crescenzo R, By K, Cohen A, Chen DY, Idoine A, Manda S, Sharman JP, Ramakrishnan V. Xu L, et al. Among authors: kingsley ec. Haematologica. 2024 Jan 25. doi: 10.3324/haematol.2023.283861. Online ahead of print. Haematologica. 2024. PMID: 38268449 Free article.
Homology and the evolution of vocal folds in the novel avian voice box.
Longtine C, Eliason CM, Mishkind D, Lee C, Chiappone M, Goller F, Love J, Kingsley EP, Clarke JA, Tabin CJ. Longtine C, et al. Among authors: kingsley ep. Curr Biol. 2024 Feb 5;34(3):461-472.e7. doi: 10.1016/j.cub.2023.12.013. Epub 2024 Jan 5. Curr Biol. 2024. PMID: 38183987
Play brick therapy to aid the social skills of children and young people with autism spectrum disorder: the I-SOCIALISE cluster RCT.
Wright B, Kingsley E, Cooper C, Biggs K, Bursnall M, Wang HI, Chater T, Coates E, Teare MD, McKendrick K, Gomez de la Cuesta G, Barr A, Solaiman K, Packham A, Marshall D, Varley D, Nekooi R, Parrott S, Ali S, Gilbody S, Le Couteur A. Wright B, et al. Among authors: kingsley e. Public Health Res (Southampt). 2023 Nov;11(12):1-137. doi: 10.3310/VGTR7431. Public Health Res (Southampt). 2023. PMID: 38095124 Free article. Clinical Trial.
I-SOCIALISE: Results from a cluster randomised controlled trial investigating the social competence and isolation of children with autism taking part in LEGO® based therapy ('Play Brick Therapy') clubs in school environments.
Wright B, Kingsley E, Cooper C, Biggs K, Bursnall M, Wang HI, Chater T, Coates E, Teare MD, McKendrick K, Gomez de la Cuesta G, Barr A, Solaiman K, Packham A, Marshall D, Varley D, Nekooi R, Parrott S, Ali S, Gilbody S, Le Couteur A. Wright B, et al. Among authors: kingsley e. Autism. 2023 Mar 29;27(8):13623613231159699. doi: 10.1177/13623613231159699. Online ahead of print. Autism. 2023. PMID: 36991578 Free PMC article.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M, Flinn IW, Levy MY, Porter RF, Burke JM, Zafar SF, Misleh J, Kingsley EC, Yimer HA, Freeman B, Rao SS, Chaudhry A, Tumula PK, Gandhi MD, Manda S, Chen DY, By K, Xu L, Liu Y, Crescenzo R, Idoine A, Zhang X, Cohen A, Huang J, Sharman JP. Shadman M, et al. Among authors: kingsley ec. Lancet Haematol. 2023 Jan;10(1):e35-e45. doi: 10.1016/S2352-3026(22)00320-9. Epub 2022 Nov 16. Lancet Haematol. 2023. PMID: 36400069 Clinical Trial.
73 results